Moose Hide Welcomes Support from BMO through Donation and Awareness Campaign in Branches Across Canada in May
The Moose Hide Campaign is an Indigenous-led initiative to end domestic and gender-based violence against women and children, particularly Indigenous women and children
BMO is supporting the Moose Hide Campaign for the second year, with a donation and multiple online and in-branch activations, including awareness through Moose Hide pins across Canada
TORONTO, May 12, 2025 /CNW/ - The Moose Hide Campaign is pleased to welcome the support of BMO for the second year, through both a donation and multiple awareness activities to promote the Campaign Day, which takes place on May 15th. The Moose Hide Campaign began as a BC-born Indigenous-led movement to end domestic and gender-based violence against women and children. It has grown into a nationwide movement of Indigenous and non-Indigenous Canadians from local communities, First Nations, governments, schools, colleges/universities, police forces and many other organizations – all committed to taking action to end this violence.
The campaign is grounded in Indigenous ceremony and traditional ways of learning and healing. A cornerstone of the Moose Hide Campaign is the wearing of the moose hide pin – a small square of moose hide, ethically sourced or donated, and hand-made by Indigenous women. Wearing the pin signifies a commitment to honour, respect, and protect the women and children in one's life, and speak out against gender-based and domestic violence.
"We're proud to continue our partnership with BMO, whose commitment to sharing the medicine—both within their organization and across the communities they serve—strengthens our collective efforts to end violence, foster safe and inclusive spaces, and promote healing through Indigenous values. Together, we are walking the path of reconciliation, cultural understanding, and healthy masculinity," said Raven Lacerte, Co-founder and Executive Director of the Moose Hide Campaign.
"As part of our Purpose, to Boldly Grow the Good in business and life, we are honoured to partner again with the Moose Hide Campaign to help raise awareness about the importance of ending gender-based violence and standing by our commitment to human rights," said Michael Bonner, Head, Canadian Personal & Business Banking Distribution, Head, BMO Enterprise Indigenous Strategy, and Co-Chair, BMO Indigenous Advisory Council. "Worn by thousands of BMO employees, the Moose Hide pins will be visible at BMO locations across the country."
BMO branch employees in Canada will be wearing their Moose Hide pins throughout the month of May to help bring awareness to the movement. In addition, information will be shared online at BMO.com and on branch digital screens.
About Moose Hide Campaign
The Moose Hide Campaign is a grassroots movement of Indigenous and non-Indigenous men and boys who are standing up against violence towards women, children and all those along the gender-continuum. It was created by Raven and Paul Lacerte, an Indigenous daughter and father from the Carrier First Nation. In 2011, while on their annual moose-hunting trip, on their traditional territory along the Highway of Tears, where so many Indigenous women were murdered or went missing, they were inspired to launch this initiative. Wearing the moose hide pin signifies a commitment to honour, respect, and protect those we love — and to help end gender-based violence in all its forms. Learn more at www.moosehidecampaign.ca.
BMO Gives. Good grows here.
Helping communities thrive by supporting the organizations that sustain them and encouraging employee giving and volunteerism is at the heart of BMO's Purpose, to Boldly Grow the Good in business and life.
In 2024, we directed more than $108 million to drive progress for communities, which included $101 million in philanthropic contributions to hundreds of charities and nonprofit organizations across North America.
Our colleagues spent over 54,000 hours volunteering in the community and contributed more than $39 million of donations through employee-driven giving in our annual campaigns.
For more information, please visit BMO.com.
SOURCE Moose Hide Campaign
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/12/c1442.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
2 days ago
- Boston Globe
Mass. Black therapists trying to diversify the workforce face an uphill battle
Advertisement 'We took the good and left the bad, and helped create this,' Labissiere, one of the clinic's cofounders, said from the Hyde Park Avenue office. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Labissiere and Wynn are rarities in this grueling industry: Black clinicians who have stuck around and own their own practice. The Child and Family Wellness Center isone of just a few Black-owned behavioral health practices in Massachusetts. In interviews with the Globe, 10 Black mental health care providers, advocates, and public officials agreed several systemic barriers keep the workforce from diversifying. The deep-seated stigma of mental illness among Black people, the time and financial costs of finishing school, and the biases embedded in the field's license exams are roadblocks for diversifying the workforce, which already suffers from massive turnover and vacancy rates. Related : Advertisement The societal costs are immense. The experienced these symptoms at higher rates, said Gemima St. Louis, vice president for workforce initiatives and specialty training and clinical psychology professor at Williams James College in Newton. As the mental health crises that COVID-19 drew out persist, stakeholders worry the behavioral health workforce won't be able to meet this rising demand with culturally competent care. 'We have a workforce that is insufficient, a workforce that lacks the diversity that is represented in the communities that have the greatest needs for mental health services,' St. Louis said. Related : Advocates are introducing measures to tackle the representation gap at its root. Clinicians working in underserved communities can have some of their student debt covered through The people working to diversify the behavioral health workforce are chipping away at a profession that has historically been for white and affluent individuals. A 2023 Advertisement One in 10 respondents in behavioral health leadership roles identified as non-Hispanic Black. Black respondents made up 9 percent of the survey's independently licensed clinicians, meaning they don't need supervision to provide treatment. Only 7.6 percent of behavioral health physicians — professionals with medical degrees — were Black. The lack of representation within the sector doesn't match the range of people needing these services, advocates say. A separate survey of insured residents across Massachusetts found that one in 10 non-Hispanic Black residents reported poor mental health in 2021, along with 15 percent of Hispanic residents. One barrier driving these disparities precedes any roadblocks Black clinicians are facing in their field: mental health care's taboo nature in their community. Black people 'might have a little bit more wealth and more opportunities, but we've never really had a chance to really process our struggles in this country,' said Nieisha Deed, founder of Recruitment into the sector can be happenstance, instead of something instilled from an early age. Larry Higginbottom, CEO of The Osiris Group clinic in Roxbury, stumbled across 'the mental health field' during a chance conversation in the late '80s with Omar Reid, a local pioneer of Black psychology and mental health. Advertisement It was a foreign concept, but '[Reed] planted a seed,' Higginbottom, now 71, said. For Melanie Robinson Findlay, owner of Upwards 'N' Onwards, an independent therapy practice in Hyde Park, the death of a best friend during high school propelled her into social work. By the time she pursued a doctorate, she had 18 years of clinical social work experience, completed a clerkship, and was even appointed to the state's Board of Registration of Social Workers. But this didn't seem like enough. She noticed her peers would find supervisors with ease. Meanwhile, 'I always felt I had to prove myself.' 'What was I missing that they have?' Robinson Findlay said. 'And when you control for all the things, there's only one thing that pops out.' Learning about the craft is only the first hurdle to entering the industry. It costs hundreds for Mental health counselors, clinical social workers, psychologists, and other professionals within the field must complete thousands of hours to qualify for a license, some of which have to be under direct supervision from another practitioner. Labissiere said the onus for supervision is placed on the aspiring clinician; they must find someone who is willing to sign off on their application and in turn, lose an employee that keeps their own practice afloat. 'These are gatekeeper positions,' Labissiere said. 'If you don't have an organization ... pushing you to become licensed, we get stuck.' Advertisement Wynn worries this mentality might choke off the next generation of clinicians of color, which is already a small group. 'People look at it as competition, but there's more than enough clients in need,' Wynn said. 'It's not a competition. It's a collaboration.' While navigating the many stressors of entering the workforce, many aspiring social workers aren't taught the financial literacy needed to start and sustain independent practices, said Malaka Mims, president of the Greater Boston Association of Black Social Workers. So many social workers are focused on passing the exam, she said, that they often say, 'I don't know how to be a business owner.' 'Social workers are trained to help others, but the field must also prioritize self care and equip social workers to care for ourselves,' Mims said. For Robinson Findlay, of Upwards 'N' Onwards, running her own practice has been a longtime dream, but it comes with its own challenges. She has scaled her fees down to accommodate low-income clients, and says she is owed thousands in private insurance reimbursements. She makes up with consulting, lecturing, and a postdoctoral fellowship. Robinson Findlay can barely afford to do this, but she can't refuse a client's request. 'Even if I say no to one, that's too many.' This story was produced by the Globe's team, which covers the racial wealth gap in Greater Boston. You can sign up for the newsletter . Tiana Woodard can be reached at
Yahoo
3 days ago
- Yahoo
LevelJump Announces 2024 Financial Results
Toronto, Ontario--(Newsfile Corp. - June 20, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), is pleased to announce its financial results for the year ended December 31, 2024. Financial and Operational Highlights Revenues were $17.7 million in 2024 compared to $12.6 million in revenues for 2023, a year over year revenue increase of 41%. Canadian Teleradiology Services, Inc., the Company's 100% owned subsidiary had EBITDA for 2024 of $3.35 million. 2024 Financial Results for fourth quarter and year Revenues of $4.8 million in Q4 2024 and $17.7 million for the year 2024 with a net profit of $1.95 million for Q4 2024 and a net profit of $1.2 million for the year 2024. EBITDA of $395,936 for Q4 2024 and $1,545,298 for the year 2024. Subsequent Events Subsequent to the year end, the Company entered an agreement to acquire two additional diagnostic imaging outpatient clinic locations in Calgary, Alberta. The transaction is expected to close towards the end of July 2025. See the Company's news release dated June 13, 2025. Management Comments "2024 was a transformative year for our Company, marked by significant growth, particularly within our clinic operations," said Mitch Geisler, CEO. "Our year-over-year revenue increased by more than 40%, and we achieved strong EBITDA performance. We are now interpreting imaging scans for approximately 200,000 patients annually across all operations. Our focus remains on driving organic growth and advancing our long-term vision for continued expansion." Non-IFRS Financial Measures This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity. For further details on the results, please refer to LevelJump's Management, Discussion and Analysis and Consolidated Financial Statements for the year ended December 31, 2024, which are available on the Company's website ( and under the Company's profile on SEDAR+ ( About LevelJump Healthcare LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve. ON BEHALF OF THE BOARD OF DIRECTORS OFLEVELJUMP HEALTHCARE CORP. Mitchell GeislerChief Executive Officerinfo@ CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable). Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan. "This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation:Iris Bincovich, CEO+1 5162104025+972-54-3012842+442037699377info@ NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo: View original content: SOURCE Innocan Pharma Corporation View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
